AC-262,536
Identifiers | |
---|---|
IUPAC name
| |
CAS Number |
|
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H18N2O |
Molar mass | 278.355 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a Ki of 5nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the anabolic action of testosterone, but only around 27% of its potency as an androgen.[1][2]
See also
References
- ↑ Cutler C, Viljanto M, Taylor P, Habershon-Butcher J, Muir T, Biddle S, Van Eenoo P (February 2021). "Equine metabolism of the selective androgen receptor modulator AC-262536 in vitro and in urine, plasma and hair following oral administration". Drug Testing and Analysis. 13 (2): 369–385. doi:10.1002/dta.2932. PMID 32959959.
- ↑ Stacchini C, Botrè F, Comunità F, de la Torre X, Dima AP, Ricci M, Mazzarino M (February 2021). "Simultaneous detection of different chemical classes of selective androgen receptor modulators in urine by liquid chromatography-mass spectrometry-based techniques". Journal of Pharmaceutical and Biomedical Analysis. 195: 113849. doi:10.1016/j.jpba.2020.113849. PMID 33383501.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.